- Global Pharma News & Resources

Janssen’s new treatment for prostate cancer receives European licence

  • Prostate cancer is the most common cancer in men in the UK,[1] resulting in over 47,000 diagnoses each year, or 129 each day[2]
  • Every 45 minutes, one man dies from prostate cancer, totalling more than 11,000 deaths each year2
  • Erleada™ (apalutamide) offers a new treatment option for men with non-metastatic castration-resistant prostate cancer who are at high risk of metastatic disease[3]


High Wycombe, 17th January 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson has today announced that the European Commission (EC) has licensed Erleada (apalutamide), for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.


Today’s licence is based on the results of the phase III SPARTAN trial, which found that apalutamide in combination with Androgen Deprivation Therapy (ADT) significantly decreased risk of death or distant metastasis by 72 percent, compared to ADT alone.3 It was also found to improve median metastasis-free survival (MFS) by over three years (40.5 months) compared to just over one year (16.2 months) in the placebo group.3


The most common Grade 3/4 treatment-emergent adverse events in the SPARTAN study were hypertension (14.3 percent vs. 11.8 percent), rash (5.2 percent vs. 0.3 percent), fall (1.7 percent vs. 0.8 percent) and fracture (2.7 percent vs. 0.8 percent).3 Treatment discontinuation due to adverse events was 10.6 percent in the apalutamide arm compared to 7 percent in the placebo arm.3 Rates of serious adverse events were similar in the apalutamide in combination with ADT arm versus placebo in combination with ADT arm (24.8 percent vs. 23.1 percent respectively).3


Prostate cancer is the most common cancer diagnosed in males in England,[4] and approximately 84 percent (34,010 people) of those diagnosed suffer from the non-metastatic form of the disease, meaning that the cancer has not spread to other parts of the body (for example, the bones).[5] If the disease is castration-resistant, it no longer responds to medical or surgical treatments that lower testosterone.[6] 90 percent of patients with nmCRPC will eventually develop bone metastases,7 which is a turning point in prostate cancer, as it is a key cause of complications and death.3 Extending the period without metastases is therefore an important treatment goal.3,[7],[8]


Commenting on the EC licence, Dr Simon Chowdhury, Consultant Medical Oncologist, Guy's and St Thomas' Hospitals, said: “Apalutamide is one of the first treatments shown to be effective in this group of patients, as phase 3 clinical data demonstrated that it significantly prolonged the time that patients with non-metastatic castration-resistant prostate cancer survived without their cancer becoming metastatic (spreading to other sites in their bodies).”


“We are pleased that the EC has authorised apalutamide for the treatment of patients with high-risk non-metastatic castration-resistant prostate cancer.” said Mohamed Lockhat, Therapeutic Area Medical Affairs Director for Oncology at Janssen UK. “At Janssen, we remain committed to our goal of developing and delivering innovative medicines that transform patients’ lives, and today’s approval brings us one step closer to achieving this.”


Editor Details

Last Updated: 20-Jan-2019